Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer

• Published in: In vivo (Athens) Vol. 35; no. 2; pp. 1141 - 1145
• Main Authors: KAGEYAMA, SUSUMU, MAEDA, KOKI, KUBOTA, SHIGEHISA, YOSHIDA, TETSUYA, OSAFUNE, TAKASHI, ARAI, YUTAKA, SOGA, HIROKI, NISHIKAWA, ZENKAI, SAKANO, YUJI, TAKIMOTO, KEITA, KIM, CHUL JANG, CHANO, TOKUHIRO, KAWAUCHI, AKIHIRO
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.03.2021
• Subjects: Administration, Intravesical; Bladder cancer; Cancer therapies; Catheters; Chemotherapy; Clinical medicine; Clinical practice guidelines; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Humans; Medical prognosis; Neoplasm Recurrence, Local - prevention & control; Patients; Retention; Tumors; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - surgery; United States > US; Japan; pirarubicin; non-muscle-invasive bladder cancer; Immediate postoperative single instillation
• ISSN: 0258-851X; 1791-7549; 1791-7549
• DOI: 10.21873/invivo.12360

This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival. Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed. Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors.